Piper Jaffray analyst Joshua Schimmer noted that Biogen reported a "strong quarter relative to consensus expectations," but added that he is not surprised by that since the company "sets guidance at levels which [he sees] as all-but-impossible to miss." Schimmer also thinks the company's CEO leaving "probably means" Biogen is not an imminent acquisition target and that a number of "key challenges" await whomever takes over. The analyst keeps Neutral rating on Biogen shares, which are up 5.5% in morning trading.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here